Detection of Staphylococcus aureus Isolates with Heterogeneous Intermediate-Level Resistance to Vancomycin in the United States
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The prevalence of heterogeneous intermediate-level resistance to vancomycin (hVISA) in Staphylococcus aureus was assessed by screening a large collection of recent isolates. Susceptibility testing by the Clinical and Laboratory Standards Institute broth microdilution method and the Etest GRD (glycopeptide resistance detection) method (bioMérieux) was performed on 4,210 clinically significant S. aureus isolates obtained in 2009 from 43 U.S. centers. Isolates with Etest GRD-positive results for hVISA were evaluated further by repeat GRD testing and population analysis profiling–area under the curve (PAP-AUC) analysis. No VISA (vancomycin MIC, 4 to 8 μg/ml) or vancomycin-resistant (MIC ≥ 16 μg/ml) strains were detected. The Etest GRD screen for hVISA was initially positive for 68 isolates (1.6%; all by teicoplanin MIC ≥ 8 μg/ml at 24 or 48 h). Among those 68 isolates, 45 were reproducibly GRD positive. PAP-AUC testing confirmed only 11 isolates as hVISA (all had reproducible GRD-positive results). The 11 hVISA isolates were from nine medical centers and appeared genetically diverse (ten different PFGE types). The rates of resistance (including intermediate) for hVISA were as follows: oxacillin, 82%; erythromycin, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%. All hVISA isolates were susceptible to linezolid, tigecycline, and ceftaroline. Our data suggest that the overall prevalence of hVISA in the United States is low (0.3%). The hVISA isolates represented 10.5% of isolates with vancomycin MICs of 2 μg/ml and 0.1% of isolates with vancomycin MICs of 1 μg/ml. The positive predictive value of GRD Etest for hVISA was 16.2% for initial screen positive and 24.4% for reproducibly positive results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lina, G., Piemont, Y., Godail-Gamot, F., Bes, M., Peter, M.-O., Gauduchon, V., Vandenesch, F., & Etienne, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313461 · Cited by 2,489
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Wootton, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.399 · Cited by 414 · cited 2×
“strain Mu3) were defined as hVISA (27).”
Background
Cited by
Antimicrobial heteroresistance: An emerging field in need of clarity
El-Halfawy, O. M., & Valvano, M. A. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-14 · Cited by 489
“Others reported that heteroresistance to vancomycin is not prevalent (51, 64, 72, 73, 80, 81, 102, 106).”
BackgroundMethicillin-Resistant Staphylococcus aureus: An Evolving Pathogen
Stryjewski, M. E., & Corey, G. R. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit613 · Cited by 334
Shariati, A., Dadashi, M., Moghadam, M. T., van Belkum, A., Yaslianifard, S., & Darban-Sarokhalil, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-69058-z · Cited by 329
Epidemiology of antimicrobial resistance in bloodstream infections
Akova, M. (2016) · Virulence · doi:10.1080/21505594.2016.1159366 · Cited by 292
Metadata
- Authors
- Richter, S. S., Satola, S. W., Crispell, E. K., Heilmann, K. P., Dohrn, C. L., Riahi, F., Costello, A. J., Diekema, D. J., & Doern, G. V.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2011-12
- Volume
- 49
- Issue
- 12
- Pages
- 4203-4207
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2164870926
- Cited by
- 55
- References
- 3
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Detection of Staphylococcus aureus Isolates with Heterogeneous Intermediate-Level Resistance to Vancomycin in the United States. https://app.cochat.ai/papers/10.1128/jcm.01152-11
- The paper
- Richter, S. S., Satola, S. W., Crispell, E. K., Heilmann, K. P., Dohrn, C. L., Riahi, F., Costello, A. J., Diekema, D. J., & Doern, G. V. (2011). Detection of Staphylococcus aureus Isolates with Heterogeneous Intermediate-Level Resistance to Vancomycin in the United States. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01152-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.